KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash & Current Investments (2016 - 2026)

Pacific Biosciences Of California has reported Cash & Current Investments over the past 16 years, most recently at $279.5 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 28.32% year-over-year to $279.5 million; the TTM value through Dec 2025 reached $279.5 million, down 28.32%, while the annual FY2025 figure was $279.5 million, 28.32% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $279.5 million at Pacific Biosciences Of California, down from $298.7 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $1.1 billion in Q2 2021 and troughed at $76.9 million in Q1 2024.
  • A 5-year average of $609.8 million and a median of $631.4 million in 2023 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: surged 1166.75% in 2021 and later tumbled 91.21% in 2024.
  • Year by year, Cash & Current Investments stood at $1.0 billion in 2021, then dropped by 26.05% to $772.3 million in 2022, then dropped by 18.24% to $631.4 million in 2023, then plummeted by 38.24% to $389.9 million in 2024, then dropped by 28.32% to $279.5 million in 2025.
  • Business Quant data shows Cash & Current Investments for PACB at $279.5 million in Q4 2025, $298.7 million in Q3 2025, and $314.7 million in Q2 2025.